How to order LIVTENCITY

Please call Takeda Patient Support at 1-855-268-1825 for questions on how to order LIVTENCITY, and our Patient Support Program, including financial assistance.

For outpatient use

LIVTENCITY Quick Start Program

Takeda will provide eligible patients immediate access to LIVTENCITY at no cost while insurance coverage and authorization are obtained.*

The LIVTENCITY Start Form authorizes Takeda Patient Support to explore a variety of financial assistance options that may be available to your patient, including the Quick Start program.

3 convenient ways to complete the LIVTENCITY Start Form:

Fax the Start Form to 1-855-268-1826

A benefits investigation is needed to determine patient eligibility after the Start Form is completed. Once eligibility requirements have been confirmed, the specialty pharmacy will coordinate the shipment of LIVTENCITY with the patient.

*Prescriber must be actively seeking coverage and will submit required documentation such as a Letter of Medical Necessity or Prior Authorization request to the insurance company.

LIVTENCITY can be ordered from one of the following Specialty Pharmacies:

Biologics, Inc
Phone: 1-866-827-8183 Fax: 1-844-854-3253

Amber Specialty Pharmacy
Phone: 1-888-370-1724 Fax: 1-833-874-3707

LIVTENCITY should be filled through one of these in-network specialty pharmacies. Sending a LIVTENCITY prescription to an alternate pharmacy may result in delay or nonfulfillment of the prescription.

For inpatient use

LIVTENCITY may be purchased directly by qualified entities* from the following distributor:

Cardinal Health Specialty
Phone: 1-866-677-4844

*Qualified entities for direct purchase include inpatient hospitals properly licensed by regulatory authorities to administer or dispense pharmaceutical products to appropriate patients, entities eligible to purchase under the Federal Supply Schedule, and 340B covered entities.

Connect with us to learn about the New Technology Add-on Payment (NTAP) for Medicare inpatient use of LIVTENCITY.

For questions or concerns about obtaining LIVTENCITY for your patients, please call Takeda Patient Support at 1-855-268-1825 Monday-Friday, 8 AM to 8 PM ET.

SEE THE SAFETY PROFILE

IMPORTANT SAFETY INFORMATION

Risk of Reduced Antiviral Activity When Co-administered with Ganciclovir and Valganciclovir

LIVTENCITY may antagonize the antiviral activity of ganciclovir and valganciclovir by inhibiting human CMV pUL97 kinase, which is required for activation/phosphorylation of ganciclovir and valganciclovir. Coadministration of LIVTENCITY with ganciclovir or valganciclovir is not recommended.

Virologic Failure During Treatment and Relapse Post-Treatment

Virologic failure due to resistance can occur during and after treatment with LIVTENCITY. Virologic relapse during the posttreatment period usually occurred within 4-8 weeks after treatment discontinuation. Some maribavir pUL97 resistance-associated substitutions confer cross-resistance to ganciclovir and valganciclovir. Monitor CMV DNA levels and check for maribavir resistance if the patient is not responding to treatment or relapses.

Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions

The concomitant use of LIVTENCITY and certain drugs may result in potentially significant drug interactions, some of which may lead to reduced therapeutic effect of LIVTENCITY or adverse reactions of concomitant drugs. Consider the potential for drug interactions prior to and during LIVTENCITY therapy; review concomitant medications during LIVTENCITY therapy and monitor for adverse reactions. Refer to the full prescribing information of LIVTENCITY for important drug interactions.

Maribavir is primarily metabolized by CYP3A4. Drugs that are strong inducers of CYP3A4 are expected to decrease maribavir plasma concentrations and may result in reduced virologic response; therefore, coadministration of LIVTENCITY with these drugs is not recommended, except for selected anticonvulsants.

Use with Immunosuppressant Drugs

LIVTENCITY has the potential to increase the drug concentrations of immunosuppressant drugs that are CYP3A and/or P-gp substrates where minimal concentration changes may lead to serious adverse events (including tacrolimus, cyclosporine, sirolimus and everolimus). Frequently monitor immunosuppressant drug levels throughout treatment with LIVTENCITY, especially following initiation and after discontinuation of LIVTENCITY and adjust immunosuppressant dose, as needed.

Adverse Reactions

The most common adverse events (all grades,> 10%) in subjects treated with LIVTENCITY were taste disturbance, nausea, diarrhea, vomiting, and fatigue.

INDICATION

LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.

Please click for Full Prescribing Information.